Expression of Ca2+-dependent activator protein for secretion 2 is increased in the brains of schizophrenic patients
暂无分享,去创建一个
Hiroshi Kunugi | Chisato Wakabayashi | Kunimasa Arima | Hiroaki Hori | K. Arima | H. Kunugi | H. Hori | K. Hattori | T. Teraishi | Noriko Yamamoto | Toshiya Teraishi | Kotaro Hattori | Haruko Tanaka | Hirofumi Uchiyama | C. Wakabayashi | Noriko Yamamoto | H. Uchiyama | Haruko Tanaka
[1] C. Antke,et al. In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders , 2009, Behavioural Brain Research.
[2] Isaac S Kohane,et al. Comment on "Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients". , 2009, The Journal of clinical investigation.
[3] F. Angelucci,et al. BDNF in schizophrenia, depression and corresponding animal models , 2005, Molecular Psychiatry.
[4] J. Deakin,et al. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. , 2009, Journal of psychiatric research.
[5] Robert Zöchling,et al. Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses , 2001, Schizophrenia Research.
[6] E. Thomas,et al. Molecular profiling of antipsychotic drug function , 2006, Molecular Neurobiology.
[7] M. Gerlach,et al. Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes , 2006, Journal of Neural Transmission.
[8] R. Levenson,et al. Regulation of dense core vesicle release from PC12 cells by interaction between the D2 dopamine receptor and calcium-dependent activator protein for secretion (CAPS). , 2005, Biochemical pharmacology.
[9] S. Itohara,et al. Impaired Cerebellar Development and Function in Mice Lacking CAPS2, a Protein Involved in Neurotrophin Release , 2007, The Journal of Neuroscience.
[10] F. Bymaster,et al. Antipsychotic‐induced gene regulation in multiple brain regions , 2010, Journal of neurochemistry.
[11] R. Yolken,et al. The Stanley Foundation brain collection and Neuropathology Consortium , 2000, Schizophrenia Research.
[12] Eric J. Nestler,et al. The molecular neurobiology of depression , 2008, Nature.
[13] S. McCarthy,et al. Serotonin receptor 2C (HTR2C) and schizophrenia: Examination of possible medication and genetic influences on expression levels , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.
[14] J. Siuciak,et al. Antidepressant-Like Effect of Brain-derived Neurotrophic Factor (BDNF) , 1997, Pharmacology Biochemistry and Behavior.
[15] T. Furuichi,et al. Differential distributions of the Ca2+‐dependent activator protein for secretion family proteins (CAPS2 and CAPS1) in the mouse brain , 2006, The Journal of comparative neurology.
[16] U. Matti,et al. CAPS Facilitates Filling of the Rapidly Releasable Pool of Large Dense-Core Vesicles , 2008, The Journal of Neuroscience.
[17] D. Sheehan,et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.
[18] G. MacQueen,et al. Increased hippocampal bdnf immunoreactivity in subjects treated with antidepressant medication , 2001, Biological Psychiatry.
[19] Teiichi Furuichi,et al. The Secretory Granule-Associated Protein CAPS2 Regulates Neurotrophin Release and Cell Survival , 2004, The Journal of Neuroscience.
[20] C. Nemeroff,et al. Involvement of neuropeptide systems in schizophrenia: human studies. , 2007, International review of neurobiology.
[21] P. Emson,et al. Immunohistochemical study of brain-derived neurotrophic factor and its receptor, TrkB, in the hippocampal formation of schizophrenic brains , 2003, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[22] H. Manji,et al. New insights into BDNF function in depression and anxiety , 2007, Nature Neuroscience.
[23] Teiichi Furuichi,et al. Autistic-like phenotypes in Cadps2-knockout mice and aberrant CADPS2 splicing in autistic patients. , 2007, The Journal of clinical investigation.
[24] A. Sampson,et al. Relationship of Brain-Derived Neurotrophic Factor and Its Receptor TrkB to Altered Inhibitory Prefrontal Circuitry in Schizophrenia , 2005, The Journal of Neuroscience.
[25] D. Sheehan,et al. M.I.N.I. Mini International Neuropsychiatric Interview , 2000 .
[26] Marie-Claude Asselin,et al. Elevated striatal dopamine function linked to prodromal signs of schizophrenia. , 2009, Archives of general psychiatry.
[27] R. Duman,et al. A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.
[28] Nils Brose,et al. Ca2+-dependent Activator Proteins of Secretion Promote Vesicular Monoamine Uptake* , 2009, Journal of Biological Chemistry.
[29] R. Belmaker,et al. Major depressive disorder. , 2008, The New England journal of medicine.
[30] K Maeda,et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients , 2000, Molecular Psychiatry.
[31] J. Lieberman,et al. Presynaptic regulation of dopamine transmission in schizophrenia. , 2011, Schizophrenia bulletin.
[32] Chiara Salio,et al. Neuropeptides as synaptic transmitters , 2006, Cell and Tissue Research.
[33] J. Kleinman,et al. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia , 2003, Molecular Psychiatry.
[34] 篤 高田,et al. M.I.N.I.(Mini-International Neuropsychiatric Interview)日本語版を用いた外来初回受診患者のスクリーニング , 2006 .
[35] K. Nakazawa,et al. Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes , 2010, Nature Neuroscience.